Vabomere™(meropenem/vaborbactam) – New drug approval
August 29, 2017 – The FDA announced the approval of The Medicines Company’s Vabomere (meropenem/vaborbactam), for the treatment of patients 18 years of age and older with complicated urinary tract infections (cUTI) including pyelonephritis caused by the following susceptible microorganisms: Escherichia coli, Klebsiella pneumoniae, and Enterobacter cloacae species complex.
Top